5.4 Preklimaterichesky Use
There is no sign for premenopausal use Raloxifene. Safety EVISTA in premenopausal women
Has not been established also its use it is not recommended.
5.5 Hepatic Deterioration
EVISTA it should be used with caution concerning patients with hepatic deterioration. Safety and efficiency have no
Established in patients with hepatic deterioration [see Clinical Pharmacology (12.3)].
5.6 Accompanying Therapy of the Estrogen
Safety of accompanying use EVISTA with a system estrogen has not been established, and its use
Not recommended.
5.7 History Hypertriglyceridemia, when Carried the Estrogen
The limited clinical data is assumed that by some women with history noted hypertriglyceridemia
(> 5.6 mmol/L or> 500 mg/dL) in reply to processing with an oral estrogen or an estrogen plus progestine can develop
The increased levels  triglycerides  when it is carried EVISTA. Women with this case record should have a whey
triglycerides  supervised, taking raloxifene.
5.8 Nephritic Deterioration
EVISTA it should be used with caution concerning patients with the moderate or serious nephritic deterioration. Safety and
Efficiency has not been established in patients with the moderate or serious nephritic deterioration [see Clinical
Pharmacology (12.3)].
5.9 History of the Cancer of a mammary gland
EVISTA has not been accordingly studied in women with previous history of a cancer of a mammary gland.
5.10 Uses in Men
There is no sign for use EVISTA in men. Raloxifene has not been accordingly studied in men
And its use is not recommended.
5.11 not Explained Uterine Bleedings
Any not explained uterine bleeding should be investigated as is clinically designated. EVISTA-considered and
At considered плацебо groups there were similar levels эндометриального fast increase [Clinical Researches (14.1, 14.2)] see.
5.12 Chest Deviations
Any not explained chest abnormality occurring during therapy EVISTA, should be investigated. EVISTA
Does not eliminate risk of a cancer of a mammary gland [Clinical Researches (14.4)] see.

Tags: drug uses, Evista, menopausal problems, osteoporosis, Raloxifene

This entry was posted on Суббота, Декабрь 19th, 2009 at 7:38 and is filed under Woman Health, Woman health articles. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.